Lirilumab

DB11754InvestigationalProtein Based Therapies

Lirilumab has been used in trials studying the treatment of Leukemia, CANCER,NOS, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia, among others.

Mechanism: Pharmacologically active on Killer cell immunoglobulin-like receptor 2DL3, Killer cell immunoglobulin-like receptor 2DL1, and Killer cell immunoglobulin-like receptor 2DL2
Curator reviewed

Resolves to

Compound

UNIIS9XDI9W918CAS1000676-41-4

Targets

P43628KIR2DL3P43626KIR2DL1P43627KIR2DL2

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lirilumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account